Oruka Therapeutics
ORKA
184 hedge funds and large institutions have $2.6B invested in Oruka Therapeutics in 2026 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 64 increasing their positions, 31 reducing their positions, and 20 closing their positions.
215% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 20
106% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 31
62% more capital invested
Capital invested by funds: $1.6B → $2.6B (+$1B)
29% more funds holding
Funds holding: 143 → 184 (+41)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
2.65% less ownership
Funds ownership: 109.18% → 106.53% (-2.6%)
62% less call options, than puts
Call options by funds: $1.98M | Put options by funds: $5.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$29.9M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$21.2M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$17.6M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$10.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$53.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$40.4M |
| 3 |
Blackstone Inc
New York
|
-$35.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.2M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$10.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DT
201
DV Trading
Chicago,
Illinois
| – | -$14.9K | -492 | Closed |
|
202
Daiwa Securities Group
Tokyo,
Japan
| – | -$4K | -116 | Closed |
|
|
ACM
203
Aster Capital Management
Dubai,
United Arab Emirates
| – | -$758 | -25 | Closed |
|
|
C
204
Covestor
London,
United Kingdom
| – | +$139 | +4 | New |
|
ORKA Hedge Fund Activity: Q1 2026 in Review
184 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2026, worth a combined $2.6B — up 62% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ORKA positions and 20 closed out — a net gain of 43 holders — while 64 added to existing stakes and 31 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $29.9M. The largest seller was Commodore Capital, exiting entirely with an estimated $53.1M sold.
- 184 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2026, up from 143 in Q4 2025.
- Funds reported $2.6B of Oruka Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
- 63 funds opened new Oruka Therapeutics positions in Q1 2026 and 20 closed out, a net change of +43 holders.
- The largest Oruka Therapeutics buyer in Q1 2026 was Avidity Partners Management, an estimated $29.9M added.
- The largest Oruka Therapeutics seller in Q1 2026 was Commodore Capital, an estimated $53.1M sold.
Based on aggregated 13F filings for Q1 2026.